XENLETA Drug Patent Profile

When do Xenleta patents expire, and when can generic versions of Xenleta launch?

Xenleta is a drug marketed by Hong Kong and is included in two NDAs. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries.

The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this compound. Additional details are available on the lefamulin acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Xenleta

Xenleta was eligible for patent challenges on August 19, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 25, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for XENLETA

International Patents:	120
US Patents:	4
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	20
Clinical Trials:	2
Patent Applications:	12
Drug Prices:	Drug price information for XENLETA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XENLETA
What excipients (inactive ingredients) are in XENLETA?	XENLETA excipients list
DailyMed Link:	XENLETA at DailyMed

See drug prices for XENLETA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XENLETA

NDA:

211673

Dosage:

SOLUTION;INTRAVENOUS

NDA:

211672

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XENLETA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nabriva Therapeutics AG	Phase 1
University of Washington	Phase 1/Phase 2
Nabriva Therapeutics AG	Phase 1/Phase 2

See all XENLETA clinical trials

Pharmacology for XENLETA

Drug Class	Pleuromutilin Antibacterial Anti-coagulant Calculi Dissolution Agent
Mechanism of Action	Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors Acidifying Activity Calcium Chelating Activity
Physiological Effect	Decreased Coagulation Factor Activity

US Patents and Regulatory Information for XENLETA

XENLETA is protected by four US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes			Y
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes			Y	Y
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes			Y	Y

Expired US Patents for XENLETA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019

International Patents for XENLETA

When does loss-of-exclusivity occur for XENLETA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Morocco

Netherlands

New Zealand

Norway

Poland

Portugal

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XENLETA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	029590	ANTIBACTERIANOS
Austria	408596
Australia	2001276389
Australia	7638901

Supplementary Protection Certificates for XENLETA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2137143	CA 2020 00046	Denmark		PRODUCT NAME: LEFAMULIN, SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/20/1457 20200728
2137143	PA2020531	Lithuania		PRODUCT NAME: LEFAMULINAS, JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/20/1457 20200727
2137143	LUC00178	Luxembourg		PRODUCT NAME: LEFAMULINE, SELS ET SOLVATES DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1457 20200728
2137143	CR 2020 00046	Denmark		PRODUCT NAME: LEFAMULIN, SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/20/1457 20200728

XENLETA Market Dynamics and Financial Trajectory: Lefamulin Sales, Patents, Competition, and Generic Risk

Last updated: August 7, 2026

XENLETA, the brand name for lefamulin, is a first-in-class pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for adults with community-acquired bacterial pneumonia, or CABP. The drug entered a crowded hospital-antibiotic market with differentiated activity and oral and intravenous formulations, but its commercial trajectory was constrained by low antibiotic reimbursement, stewardship controls, limited use outside CABP, and the financial distress of its original commercial sponsor, Nabriva Therapeutics.

Nabriva reported rapid percentage growth from a small base, but XENLETA did not reach the commercial scale needed to support an independent antibiotic company. Nabriva entered bankruptcy proceedings in 2021, and XENLETA’s U.S. commercial rights subsequently moved to Melinta Therapeutics. Public disclosures after the transaction do not separately report XENLETA revenue, making precise current sales estimates unavailable.

What is XENLETA and how does lefamulin work?

XENLETA contains lefamulin, a semisynthetic pleuromutilin antibiotic. It binds to the peptidyl transferase center of the bacterial 50S ribosomal subunit and inhibits protein synthesis. Its mechanism differs from those of fluoroquinolones, macrolides, beta-lactams, and tetracyclines.

The FDA approved XENLETA on Aug. 19, 2019, for treatment of CABP caused by susceptible organisms in adults. The approval covered both intravenous and oral administration, which supports hospital initiation followed by oral step-down treatment. Recommended regimens are:

Formulation	Dose	Typical treatment
Intravenous lefamulin	150 mg every 12 hours	Five days
Oral lefamulin	600 mg every 12 hours	Five days

The label includes activity against common CABP pathogens, including Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and atypical organisms such as Mycoplasma pneumoniae and Chlamydophila pneumoniae. XENLETA does not have a broad gram-negative profile and is not positioned as a general hospital antibiotic.

How large is the XENLETA market?

The addressable market is the adult CABP segment requiring hospitalization or treatment with a branded oral antibiotic. That market is commercially narrower than the total pneumonia market because many patients receive low-cost generic beta-lactams, macrolides, or fluoroquinolones.

XENLETA competes in several settings:

• Hospitalized adults requiring empiric CABP therapy.
• Patients with contraindications or intolerance to fluoroquinolones.
• Patients with suspected atypical pathogens.
• Patients needing oral step-down therapy after intravenous treatment.
• Cases in which resistance, drug interactions, or safety concerns limit standard options.

The main commercial barriers are hospital formulary restrictions, infectious-disease approval requirements, generic competition, and payer pressure. Antibiotic use is also subject to stewardship programs that intentionally limit promotion and broad utilization.

XENLETA’s value proposition is strongest where clinicians want a non-fluoroquinolone option with both intravenous and oral formulations. Its value is weaker in uncomplicated outpatient pneumonia, where generic antibiotics are substantially cheaper.

What were XENLETA’s reported sales and financial trajectory?

Nabriva’s public filings show growth in XENLETA product revenue after launch, but from a low base. Reported figures varied by accounting period and product classification.

Period	Commercial event	Public financial implication
August 2019	FDA approval	Commercial launch followed in the U.S.
2019	Initial launch period	Limited launch-quarter revenue
2020	COVID-19 disruption	Reduced hospital diagnoses and elective activity affected antibiotic demand
2021	Commercial expansion attempt	Product revenue increased, but operating losses and liquidity pressure continued
2021-2022	Nabriva restructuring and bankruptcy process	U.S. commercial assets and XENLETA rights transferred or reorganized
2022 onward	Melinta commercialization	Separate XENLETA sales were not publicly disclosed

Nabriva reported approximately $6.6 million in XENLETA product sales in 2020 and approximately $12.4 million in 2021, based on its SEC reporting. The increase represented strong percentage growth but remained small relative to the cost of maintaining a commercial organization, manufacturing supply, regulatory infrastructure, and field sales operations.

The financial trajectory was therefore negative in absolute terms despite improving product sales. Nabriva’s challenge was not only demand generation. It also faced:

• High launch and commercialization expenses.
• Limited hospital adoption.
• Pressure from generic antibiotics.
• COVID-19-related reductions in respiratory infections and hospital activity.
• Manufacturing and supply-chain costs.
• Insufficient cash to fund continued independent operations.

Nabriva’s financial distress materially changed the ownership and commercialization profile of XENLETA. Melinta had an established hospital-antibiotic portfolio and commercial infrastructure, making the product more compatible with a portfolio model than with a standalone public-company launch strategy.

Which companies market or control XENLETA?

Nabriva Therapeutics developed and launched XENLETA in the United States. Following Nabriva’s restructuring, Melinta Therapeutics became the principal commercial entity associated with XENLETA in the U.S. Melinta’s portfolio includes hospital anti-infectives, allowing XENLETA to be promoted alongside products used by infectious-disease specialists and hospital pharmacists.

Nabriva also had relationships with regional and international partners. Commercial rights outside the United States were subject to separate arrangements, and geographic commercialization has not matched the U.S. launch model.

The ownership transition reduced the probability that XENLETA would be discontinued solely because of the original sponsor’s liquidity position. It did not eliminate market constraints. A portfolio owner can retain a niche antibiotic with lower standalone revenue if the product contributes to hospital-account access, combined sales coverage, or portfolio economics.

What patents protect XENLETA and lefamulin?

XENLETA’s intellectual-property protection is based on a combination of compound, formulation, and regulatory exclusivity rights. The relevant protection is not limited to one patent.

The principal patent categories are:

Protection category	Commercial role
Lefamulin compound patents	Protect the active pharmaceutical ingredient and related chemical entities
Pharmaceutical-composition patents	Cover dosage forms, excipients, and formulations
Intravenous formulation patents	Protect injectable product design and administration
Method-of-use patents	Cover treatment of bacterial infections, including CABP-related uses
Regulatory exclusivity	Delays certain abbreviated generic filings independently of patent expiry

The FDA granted XENLETA five-year new chemical entity exclusivity from the Aug. 19, 2019 approval date. The standard NCE period therefore ran to Aug. 19, 2024. Any pediatric exclusivity would have extended applicable regulatory protection by six months if awarded and properly listed.

The practical generic-entry date depends on more than NCE exclusivity. It is affected by:

1. Orange Book-listed patents.
2. Patent expiration dates and patent-term adjustment.
3. Paragraph IV certifications.
4. Litigation filed within the statutory 45-day period.
5. Court decisions or settlements.
6. Whether a generic applicant seeks approval for oral, intravenous, or both formulations.
7. Regulatory treatment of method-of-use patents.

Because XENLETA is a relatively recent small-molecule approval, patent expiry may extend beyond the NCE period. Patent term must be assessed patent by patent rather than inferred from the 2024 regulatory-exclusivity date.

What is the Orange Book status of XENLETA?

XENLETA is an FDA-approved small-molecule drug and is eligible for Orange Book listing of patents that claim the drug substance, drug product, or approved method of use. Orange Book protection is distinct from biologic patent and interchangeability rules because XENLETA is not a biologic.

The Orange Book analysis should distinguish:

• Lefamulin active-ingredient claims.
• Oral tablet claims.
• Intravenous formulation claims.
• Approved-use claims.
• Patent listings that may be challenged through Paragraph IV certification.

The FDA’s electronic Orange Book is the controlling source for current listing status and expiration information. A patent may remain legally relevant even if it is not a blocking compound patent, particularly when it covers a commercially important formulation or route of administration.

When does XENLETA lose exclusivity?

XENLETA’s five-year NCE exclusivity expired in August 2024, subject to any applicable pediatric extension. Patent protection may continue after regulatory exclusivity.

Exclusivity or protection	Relevant timing
FDA approval	Aug. 19, 2019
Five-year NCE exclusivity	Through Aug. 19, 2024
Potential pediatric extension	Six additional months if granted
Patent protection	Patent-specific; may extend beyond NCE exclusivity
Generic launch	Depends on ANDA approval, patent challenges, litigation, and settlement terms

The end of NCE exclusivity permits certain ANDA filings but does not guarantee immediate generic launch. A generic applicant may file a Paragraph IV certification against listed patents. If the brand owner sues within 45 days, FDA approval can be stayed for up to 30 months, subject to statutory exceptions and court developments.

No major public Paragraph IV litigation involving XENLETA had become a visible market event in the public disclosures reviewed through the latest available company reporting. That does not establish that no ANDA challenge exists; confidential or nonpublic filing activity cannot be inferred from the absence of litigation reporting.

How does XENLETA compare with competing pneumonia antibiotics?

XENLETA competes against both branded and generic therapies.

Drug	Class	Main commercial advantage	Main limitation
XENLETA, lefamulin	Pleuromutilin	Novel mechanism; IV and oral dosing; non-fluoroquinolone option	Price, limited indication, QT-related concerns, restricted use
NUZYRA, omadacycline	Aminomethylcycline tetracycline	CABP and acute bacterial skin and skin-structure infection indications	High cost; nausea and gastrointestinal tolerability
AVELOX and generic moxifloxacin	Fluoroquinolone	Low generic cost and established use	Safety warnings, resistance, QT and drug-interaction concerns
DELAFLOXACIN, Baxdela	Fluoroquinolone	Gram-positive and gram-negative coverage; IV and oral forms	Narrow commercial scale and fluoroquinolone class concerns
Ceftaroline	Cephalosporin	Established hospital use and MRSA activity	Intravenous-only treatment and beta-lactam limitations
Generic beta-lactam plus macrolide	Multiple classes	Low cost and guideline familiarity	Combination therapy and resistance limitations

XENLETA’s closest branded commercial comparison is NUZYRA because both are newer antibiotics with CABP positioning and premium pricing. XENLETA has a simpler five-day treatment course and a differentiated mechanism. NUZYRA has the advantage of an additional skin-infection indication, which expands its sales base.

What is the biosimilar risk for XENLETA?

XENLETA has no biosimilar risk because lefamulin is a chemically synthesized small-molecule drug. The relevant competitive threat is generic substitution through the ANDA pathway.

Generic risk is likely to emerge first in the oral tablet market if an applicant can reproduce the reference product’s formulation and meet bioequivalence requirements. Intravenous competition may require separate development and manufacturing capabilities. If key formulation or method-of-use patents remain listed, generic approval may be delayed even after NCE exclusivity ends.

How strong is the XENLETA patent estate?

XENLETA’s patent estate is commercially meaningful but not equivalent to the protection around a high-revenue chronic medicine. Its strengths are the recency of approval, the potential for formulation and method-of-use layering, and the difficulty of rapidly establishing a hospital-antibiotic manufacturing and sales platform.

Its weaknesses are the small revenue base, the availability of numerous generic CABP treatments, and the limited number of approved indications. Patent strength should be evaluated against claim scope, remaining term, Orange Book listing status, validity risk, and the likelihood that a generic can design around a formulation or use claim.

A compound patent covering lefamulin would normally provide stronger exclusion than a narrow formulation or treatment-method patent. A formulation patent may still have high commercial value if the listed formulation is necessary for the approved oral or intravenous product.

What generic launch scenarios exist for XENLETA?

Three scenarios are commercially plausible:

Delayed generic entry

A generic manufacturer files an ANDA with Paragraph IV certifications, the patent holder brings litigation, and FDA approval is delayed by the statutory stay or court proceedings. Under this scenario, XENLETA retains branded pricing for a longer period but may face contracting pressure once a challenger becomes visible.

Limited oral generic entry

A generic tablet launches while intravenous supply remains branded. This would likely create the greatest initial price pressure in outpatient and hospital step-down use. The branded product could retain some share where hospitals value a single IV-to-oral pathway.

Broad generic substitution

Oral and intravenous generics enter after patent resolution or settlement. Price erosion would likely be substantial because CABP treatment has multiple low-cost alternatives. XENLETA could remain commercially relevant in patients with resistance, intolerance, or contraindications to standard therapies, but volume would depend on formulary positioning.

What patent litigation and settlement agreements affect XENLETA?

No widely reported high-value XENLETA patent settlement had materially reshaped the market in the public disclosures reviewed. The absence of a reported settlement leaves generic timing dependent on Orange Book listings, ANDA filings, and any future Paragraph IV litigation.

A settlement could include an agreed generic entry date, a license, restrictions on the generic’s formulation or indication, or a launch date tied to patent expiration. For XENLETA, an authorized generic arrangement could also be commercially attractive because the product’s modest sales base limits the value of prolonged litigation relative to legal expense.

What is XENLETA’s revenue exposure and investment outlook?

XENLETA is unlikely to generate blockbuster revenue under its current CABP-only positioning. Its investment value depends on portfolio economics rather than standalone scale.

Key revenue drivers are:

• Hospital formulary penetration.
• Use in patients unsuitable for fluoroquinolones.
• Conversion from intravenous to oral therapy.
• Net price after payer discounts.
• Antibiotic stewardship policies.
• Generic timing.
• Expansion into additional indications.
• Manufacturing cost and supply reliability.

The product’s original launch showed that clinical differentiation did not translate into rapid commercial scale. Melinta’s ownership improves access to hospital customers and reduces standalone infrastructure requirements, but it cannot remove generic competition or the structural limits of the CABP market.

Key Takeaways

• XENLETA is lefamulin, a first-in-class pleuromutilin approved by the FDA in 2019 for adult CABP.
• Nabriva reported approximately $6.6 million in 2020 product sales and approximately $12.4 million in 2021.
• Nabriva’s bankruptcy and restructuring shifted XENLETA’s commercial position to Melinta Therapeutics.
• The five-year FDA NCE exclusivity period ended in August 2024, subject to any pediatric extension.
• Patent expiry may extend beyond regulatory exclusivity and must be assessed through current Orange Book listings.
• XENLETA has generic risk, not biosimilar risk.
• The strongest commercial differentiators are its novel mechanism and IV-to-oral treatment pathway.
• The main constraints are low-cost generic competition, hospital stewardship, limited indications, and a modest addressable market.
• XENLETA is more valuable as part of a hospital-antibiotic portfolio than as a standalone growth asset.
• Public post-acquisition disclosures do not provide a separate current revenue series for XENLETA.

FAQs

Is XENLETA still marketed in the United States?

XENLETA has been associated with Melinta Therapeutics following Nabriva’s restructuring. Current commercial availability and contracting status depend on the owner’s distribution and hospital-access strategy.

Is lefamulin available as a generic?

The end of FDA NCE exclusivity permits certain generic filings, but generic availability depends on ANDA approval, Orange Book patents, Paragraph IV litigation, settlements, and manufacturing readiness.

Does XENLETA treat MRSA pneumonia?

Lefamulin has activity against susceptible gram-positive organisms, including some S. aureus strains, but treatment decisions depend on susceptibility, local resistance, infection severity, and the FDA-approved indication.

Can XENLETA be used for outpatient pneumonia?

The oral formulation permits outpatient treatment in appropriate adults with CABP. Cost, payer coverage, antimicrobial stewardship, and clinical suitability limit routine use against low-cost generic alternatives.

What is the main commercial risk to XENLETA?

The main risk is price and volume erosion from generic lefamulin or competing low-cost antibiotics after patent and regulatory barriers no longer prevent market entry.

References

1. U.S. Food and Drug Administration. (2019). FDA approves new antibiotic to treat community-acquired bacterial pneumonia. https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia

2. U.S. Food and Drug Administration. (2023). XENLETA (lefamulin) prescribing information. Nabriva Therapeutics/Melinta Therapeutics.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Electronic Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. Nabriva Therapeutics plc. (2022). Annual report on Form 10-K for the fiscal year ended Dec. 31, 2021. U.S. Securities and Exchange Commission.

5. Nabriva Therapeutics plc. (2021). Quarterly and current reports concerning XENLETA commercialization and corporate restructuring. U.S. Securities and Exchange Commission.

6. Melinta Therapeutics, LLC. (2022). XENLETA product information and prescribing resources. https://www.melinta.com